Cho S-F, Lin L, Xing L, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020;4(17):4195-4207.

Documenti analoghi

• The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models
  di: Cho, Shih-Feng, et al.
  Pubblicazione: (2020)
• Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
  di: Zhu, Yuan Xiao, et al.
  Pubblicazione: (2011)
• Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
  di: I. G. Rekhtina, et al.
  Pubblicazione: (2019-04-01)
• Efficiency of pomalidomide therapy in patients with multiple myeloma refractory to lenalidomide
  di: I. G. Rekhtina, et al.
  Pubblicazione: (2019-04-01)
• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
  di: Paludo, Jonas, et al.
  Pubblicazione: (2017)